Abbreviations: AUC inf , area under the curve from time zero to extrapolated to infinity; AUC t , area under the curve from time zero to the last observed concentration; Cl, clearance; C max , peak concentration; F/M ratio, fetal-to-maternal ratio; i.v., intravenous; LLoQ, lowest limit of quantification; PK, pharmacokinetics; P, plasma; T 1/2 , terminal half-life; T max , time to peak concentration; V ss , apparent volume of distribution at steady state. 
| INTRODUC TI ON
Pregnant women may need analgesia during pregnancy, and most are given analgesics during delivery.
1,2 Some women undergo urgent non-obstetric surgery during pregnancy, and some life-threatening birth defects may necessitate fetal surgery before birth. 3, 4 In these cases, appropriate pain management is necessary during surgery and postoperatively.
Abdominal surgery is the most common surgical procedure in pregnant women. 3 Epidural analgesia is the gold standard for pain management after laparotomy and in labor. 2 When epidural analgesia is used, a local anesthetic is often combined with an opioid agonist to enhance the analgesic effect, to decrease the required amount of local anesthetic and to improve patient satisfaction. 5 Epidural puncture is contraindicated in some patients and parturients, for example, in patients receiving anticoagulant medication or having other bleeding disorders. In these cases, analgesics must be given intravenously (i.v.) or by other administration routes.
6-8
Oxycodone is an opioid agonist that has been used for managing moderate and severe pain for a century. During the last two decades, the global use of oxycodone has increased extensively. 9 Abdominal
surgery, both open and laparoscopic, and labor are associated with significant visceral pain. 10 As oxycodone is a highly effective opioid for visceral pain, 11 it is assumed to be a feasible opioid analgesic in pregnant women for management both peri-and postoperative pain in non-obstetric surgery and labor pain.
6,9
Fetal exposure is a concern when using opioids during pregnancy. Oxycodone, like other opioids, crosses the placenta freely, 6, 12 which becomes clinically important because higher doses can cause fetal sedation and compromise respiratory and neurological function immediately after birth.
To our knowledge, there are no previous studies of the pharmacokinetics (PK) of oxycodone in pregnant ewes. The aims of this experimental study with pregnant sheep were, first, to describe the PK of i.v. oxycodone in the ewe and, secondly, to evaluate the fetal exposure to oxycodone and its metabolites in late pregnancy. Our study hypothesis was that the fetal exposure would be similar to maternal exposure after oxycodone administration to the ewe.
| MATERIAL AND ME THODS
The present study is a part of the KuBiCo (Kuopio Birth Control) The surgical procedure included the placement of catheters into the fetal internal jugular vein and carotid artery. The surgical procedure has been described in detail earlier. 13 In short, a midline abdominal incision was made to access the uterus. After hysterotomy, fetal head and upper body were delivered, and catheters were inserted into the carotid artery and the internal jugular vein, placing the catheter tips in the ascending aorta and the superior vena cava.
Maternal blood samples were collected from the external jugular vein before the oxycodone administration, and 2, 10, 30 and
Key Message
Oxycodone pharmacokinetics in pregnant ewe was determined. After maternal oxycodone administration, fetal accumulation of oxymorphone, an active metabolite of oxycodone, was observed.
60 minutes, and 2, 4, 7, 10 and 24 hours after the oxycodone bolus.
In addition, two parallel maternal and fetal blood samples were taken; the first when the fetal catheters were in place and the second at the end of surgery. The fetal blood samples were obtained from the arterial catheter. The blood samples were taken into EDTA tubes, turned six to eight times and then centrifuged at 2500 g for 10 minutes. Following this, the separated plasma was divided into two Eppendorf tubes and stored at −70°C until analysis in a single patch in Admescope Ltd (Oulu, Finland).
Oxycodone concentration was measured using an ultra-performance liquid chromatography mass spectrometry system. 14 The linear calibration ranges (ng·mL −1 ) were fitted as follows: oxycodone 0.05-1000, oxymorphone 0.1-500, noroxymorphone 0.2-1000, and noroxycodone 0.05-100. Accuracies were between 101% and 124%
at the lowest limit of quantification (LLoQ) and between 85% and 112% above the LLoQ. Precisions were 0.9%-14% over the entire range of calibration. All concentrations of oxycodone and its metabolites are reported as corresponding hydrochlorides.
| Statistical analyses
No formal sample size calculation was performed, but the sample of 10 pregnant sheep available was considered to provide pertinent data on the oxycodone PK in pregnant sheep and the fetal exposure 
| Ethical approval
The study protocol was reviewed and approved by the National 
| D ISCUSS I ON
To the best of our knowledge, this was the first study to evaluate oxycodone PK in pregnant sheep. The plasma clearance of oxycodone The fetal P-oxycodone concentrations were mainly similar to those in the maternal plasma in samples obtained 1-2.5 hours after oxycodone administration. Few higher fetal P-oxycodone concentrations were observed in the i.v.-group, the highest F/M ratio being 1.95, but not in the Epidural-group. In our previous study with human parturients, P-oxycodone was similar in the maternal and the umbilical plasma, and no high oxycodone F/M ratios were observed.
6
One of the limitations of the present study was that the first parallel blood samples were taken when the fetal catheters were in place and the second at the end of surgery. As these times vary from pair to pair, the calculation points vary accordingly.
The novel and clinically important finding of the present study was that the fetal plasma concentrations of oxymorphone, an active metabolite of oxycodone, exceeded those in the maternal plasma.
Oxymorphone concentrations in the fetal plasma were indeed 2.1-fold higher after i.v. administration and 1.3-fold higher after epidural administration than in the maternal plasma. To the best of our knowledge, there are no previous studies showing fetal oxymorphone accumulation. Oxymorphone is rarely used for labor analgesia, 18 but it is metabolized from oxycodone via CYP2D6 in humans.
Oxymorphone accumulation in fetus is a concern, because oxymorphone has almost 50-fold higher affinity for the μ-opioid receptor compared with oxycodone. It is assumed that high oxymorphone concentrations are associated with an increased risk for adverse effects in newborn.
19
Possible explanations for oxymorphone accumulation are related to its metabolism and increased fetal uptake. In sheep, fetal development and activity of CYP enzymes are slower than in humans.
20
In human oxycodone metabolism, the CYP3A4 pathway to noroxycodone is the most significant, whereas CYP2D6 metabolism to oxymorphone has a minor role. In the present study, P-noroxycodone remained low, while oxymorphone was the primary metabolite.
Differences in human and sheep pharmacokinetics, as well as immature CYP activity in sheep fetuses, may partly explain the high fetal oxymorphone concentrations observed. The possibility of fetal uptake warrants further studies. Oxymorphone placental permeability has not been established, but opioids in general cross the placenta freely because they have low molecular weight and are highly liposoluble.
21
In human parturients after 2-5 mg i.v. oxycodone, umbilical oxymorphone concentrations were below 0.12 ng·mL −1 . 6 In that study, TA B L E 1 The maternal pharmacokinetic variables after oxycodone administration. Data are presented as median (minimum-maximum)
The maternal plasma concentrations of oxycodone after 0.5 mg·kg −1 intravenous oxycodone i.v. oxycodone, the peak P-oxymorphone was below 2.5 ng·mL 
oxycodone.
14 No severe adverse effects were observed.
In the present study, the fetal P-oxycodone was lower than the maternal P-oxycodone after epidural administration. In the ewes, 
| CON CLUS ION
The pharmacokinetics of oxycodone in pregnant sheep were described for the first time. In particular, oxymorphone accumulation to the fetus was observed after i.v. and epidural administration of oxycodone to the ewe. Further studies are required to evaluate the clinical relevance of these results with this sheep model.
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